YunYenMD

Oncology • Duarte, CA

Academic practice

Join to view full profile

Dr. Yen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Yen's full profile

Already have an account?

Office
1500 Duarte Rd
Duarte, CA 91010
Phone+1 626-359-8111

Fax+1 626-408-3911

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1991 - 1993
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1991
St Luke's University HospitalResidency, Internal Medicine, 1987 - 1990
Taipei Medical UniversityClass of 1982

Certifications & Licensure

CA State Medical License 1989 - 2026
CT State Medical License 1990 - 1993

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2006-2014
Top Doctors:LA Area Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Top Doctors:Southern California Castle Connolly, 2012
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Oxaliplatin in Treating Patients With Liver Cancer Start of enrollment: 2002 Sep 01
Completed
Phase 2
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors Start of enrollment: 2006 May 01
Completed
Phase 1, Phase 2
3-AP in Treating Patients With Advanced or Metastatic Solid Tumors Start of enrollment: 2006 Dec 01
Completed
Phase 1
High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer Start of enrollment: 2006 Apr 01
Completed
Phase 1
Safety Study of CALAA-01 to Treat Solid Tumor Cancers Start of enrollment: 2008 May 01
Terminated
Phase 1
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer Start of enrollment: 2014 Jun 11
Completed
Phase 1
A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer Start of enrollment: 2006 Nov 01
Terminated
Phase 2
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) Start of enrollment: 2020 Jan 10
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

210 citations
FZD7 has a critical role in cell proliferation in triple negative breast cancer
L. Yang, Xiwei Wu, Yujun Wang, K. Zhang, J. Wu
Oncogene. 2011-10-27
95 citations
miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis
Xianghui Fu, Zhipeng Meng, Wei Liang, Y Tian, Xiaoqiong Wang
Oncogene. 2014-08-21
35 citations
miR-103/107 prolong Wnt/β-catenin signaling and colorectal cancer stemness by targeting Axin2.
Hsin Yi Chen, Yaw Dong Lang, Han Nan Lin, Yun Ru Liu, Chun Chieh Liao
Scientific Reports. 2019-07-04

Press Mentions

Tang Prize Laureates Reflect on the Breakthroughs Made Possible by Cytokine ResearchNovember 27th, 2021

Other Languages

Chinese (Mandarin)